<DOC>
	<DOC>NCT00163085</DOC>
	<brief_summary>To determine the effects of the NMDA antagonist, CP-101,606, in subjects with Parkinson's Disease</brief_summary>
	<brief_title>The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>30 80yearold PD patients (UK Parkinson's Disease Brain Bank criteria) with a Hoehn &amp; Yahr stage score of 25 in the "off" state. Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2006</verification_date>
</DOC>